Implementing a Mobile Stroke Unit Program in the United States Why, How, and How Much?

被引:51
|
作者
Rajan, Suja [1 ]
Baraniuk, Sarah [1 ]
Parker, Stephanie [2 ]
Wu, Tzu-Ching [2 ]
Bowry, Ritvij [3 ]
Grotta, James C. [3 ]
机构
[1] Univ Texas Houston, Sch Publ Hlth, Houston, TX USA
[2] Univ Texas Hlth Sci Ctr Houston, Dept Neurol, Houston, TX 77030 USA
[3] Mem Hermann Texas Med Ctr, Houston, TX 77030 USA
关键词
ACUTE ISCHEMIC-STROKE; TISSUE-PLASMINOGEN ACTIVATOR; COST-EFFECTIVENESS; POOLED ANALYSIS; TIME; THROMBOLYSIS; NINDS; PA; TELEMEDICINE; ASSOCIATION;
D O I
10.1001/jamaneurol.2014.3618
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
IMPORTANCE There are many ways a mobile stroke unit (MSU) might prove valuable for patients with ischemic and hemorrhagic stroke, such as earlier recognition, more accurate triage, improved management of blood pressure and other critical physiological variables, and eventually earlier implementation of effective therapies. The MSU may be particularly valuable for treatment of patients with acute ischemic stroke with tissue plasminogen activator (tPA) within 4.5 hours of symptom onset, the most evidence-based effective emergency treatment for the most prevalent stroke diagnosis. OBJECTIVES To review existing data on prehospital stroke treatment, especially relevant to MSU technology, to identify gaps in our understanding of MSU feasibility, especially relevant to applying the MSU strategy in the United States, and to describe the Houston MSU program and clinical trial. EVIDENCE REVIEW Published data from English-language journals in PubMed from 1995 to present reviewing early treatment with tPA and prehospital stroke evaluation and treatment. FINDINGS The MSU may result in an overall shift toward earlier evaluation and treatment with tPA, particularly into the first hour after symptom onset, leading to substantially better outcomes. As a result of improved clinical outcomes owing to earlier treatment, the costs of an MSU program may be offset by a reduction in the costs of long-term stroke care and an increase in quality-adjusted life-years, thereby supporting more widespread use of this technology. To make MSU deployment more practical, the vascular neurologist aboard the MSU must be replaced by a remote vascular neurologist connected to the MSU by telemedicine, reducing manpower requirements and costs. CONCLUSIONS AND RELEVANCE The MSU strategy could dramatically transform the way acute stroke is managed in the United States. A prospective study evaluating the logistics, outcomes, and cost-effectiveness of this approach is needed and under way.
引用
收藏
页码:229 / 234
页数:6
相关论文
共 50 条
  • [21] HOW MUCH DO UNITED-STATES POWERPLANTS COST
    不详
    ELECTRICAL WORLD, 1985, 199 (03): : 87 - 88
  • [22] Privatizing social security in the United States: Why and how
    Kotlikoff, LJ
    FISCAL POLICY: LESSONS FROM ECONOMIC RESEARCH, 1997, : 213 - 258
  • [23] GRADUATE STUDY IN UNITED-STATES - WHY AND HOW
    WHEALE, JL
    BULLETIN OF THE BRITISH PSYCHOLOGICAL SOCIETY, 1976, 29 (MAY): : 140 - 142
  • [24] How much warfarin for stroke?
    不详
    AGE AND AGEING, 2000, 29 (06) : 488 - 488
  • [25] INTERFACING STUDENT TO COMPUTER - WHY, HOW AND HOW MUCH
    HOWARD, G
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1975, 170 (AUG24): : 1 - 1
  • [26] Sport Therapy for Hypertension: Why, How, and How Much?
    Manfredini, Fabio
    Malagoni, Anna M.
    Mandini, Simona
    Boari, Benedetta
    Felisatti, Michele
    Zamboni, Paolo
    Manfredini, Roberto
    ANGIOLOGY, 2009, 60 (02) : 207 - 216
  • [27] Implementing a Whole Blood Program: How Much Do You Really Need?
    Hu, Parker J.
    Uhlich, Rindi
    Lammers, Daniel T.
    Betzold, Richard
    Jansen, Jan O.
    Kerby, Jeffrey D.
    Holcomb, John B.
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2023, 237 (05) : S530 - S531
  • [28] How much is program worth?
    不详
    SCIENCE, 1996, 272 (5260) : 343 - 343
  • [29] Calcifediol: Why, When, How Much?
    Donati, Simone
    Marini, Francesca
    Giusti, Francesca
    Palmini, Gaia
    Aurilia, Cinzia
    Falsetti, Irene
    Iantomasi, Teresa
    Brandi, Maria Luisa
    PHARMACEUTICALS, 2023, 16 (05)
  • [30] PARACETAMOL - WHEN, WHY AND HOW MUCH
    SHANN, F
    JOURNAL OF PAEDIATRICS AND CHILD HEALTH, 1993, 29 (02) : 84 - 85